GlaxoSmithKline PLC
NYSE:GSK
GlaxoSmithKline PLC
NYSE:GSK
Price:
58.45
USD
-0.07%
Market Closed
Market Cap:
$119.2B
Relative Value
The Relative Value of one
GSK
stock under the Base Case scenario is
67.94
USD.
Compared to the current market price of 58.45 USD,
GlaxoSmithKline PLC
is
Undervalued by 14%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GSK
Relative Value
Base Case
67.94
USD
Undervaluation 14%
Multiples Across Competitors
GSK Competitors Multiples
GlaxoSmithKline PLC Competitors
GlaxoSmithKline PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
GlaxoSmithKline PLC
NYSE:GSK
|
87.3B USD | 2.7 | 15.3 | 7.7 | 11 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
990.8B USD | 15.2 | 48 | 32.3 | 34.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.6B USD | 6.3 | 22 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.4B CHF | 4.7 | 30.5 | 12.9 | 15 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.4B GBP | 5.4 | 31 | 17.1 | 24.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
237.5B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD | 4.6 | 16.3 | 10.2 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.3 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.2B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122.1B USD | 2.5 | 17.3 | 6.8 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
